ABS-201 / Absci Corp - LARVOL DELTA

Prolactin Receptor Antagonism by ABS-201 Drives Hair Follicle Growth and Stem/Progenitor Cell Expansion in Human Male Scalp Skin (EADV 2026) - "Introduction Background: Current FDA-approved therapies for androgenetic alopecia provide limited and often insufficiently durable clinical benefit, underscoring the need for therapeutic strategies beyond minoxidil and 5α-reductase inhibition. These preclinical findings independently confirm the inhibitory role of PRL in human male scalp hair follicle growth and provide the first direct evidence that antibody-mediated antagonism of PRLR signaling stimulates human HF growth ex vivo. The observed effects occur directly in androgen-sensitive male scalp skin and extend across multiple biological levels, including anagen maintenance, matrix keratinocyte activity, hair shaft production, growth factor expression, reduction in catagen-associated HF remodeling and epithelial hair follicle stem/progenitor cell support. Together, these data identify ABS-201 as a promising, first-in-class, non-androgen-targeting therapeutic candidate for androgenetic alopecia, with potential to..."

Alopecia • Immunology • Inflammation • CD34 • FGF7 • IGF1 • PRLR • STAT5 • STAT5AWqe

Absci…reported interim Phase 1 data from the HEADLINE trial for ABS-201, which reported positive results on safety and pharmacokinetics - "The trial began dosing its first participants in December 2025, and Absci expects further clinical readouts over the next two years."

P1 data • Alopecia • Immunology

ABS-101 (anti-TL1A antibody) (GlobeNewswire) - "Interim data for the Phase 1 clinical trial for ABS-101 demonstrated extended half-life as compared to first-generation anti-TL1A competitor programs, with no apparent impact of ADA on PK, with the overall safety profile being favorable with no serious adverse events reported. With this data, Absci will explore potential partnership and outlicensing opportunities for ABS-101, consistent with the company's business strategy, as well as first-in-class indication expansion opportunities for this target. The company has made the strategic decision not to initiate additional later-stage development trials for ABS-101 internally at this time. Instead, Absci will allocate capital and resources toward expanded and accelerated clinical development of ABS-201 in endometriosis, where there is a high unmet medical need and market opportunity."

Clinical • P1 data • Immunology • Inflammatory Bowel Disease